Open Orphan: hear the latest on this pharma stock
16th March 2022 11:54
Share on
Chair Cathal Friel, chief executive officer Yamin Mo Khan of Open Orphan (LSE:ORPH)present and answer a range of investor questions. The event, held on 15 March 2022, is brought to you by our friends at Investor Meet Company.
Highlights
Q&A: 31:10
About the Company
Open Orphan is a European-focused rare and orphan drug consulting services platform. The company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The company is targeting rapid growth in one of the fastest-growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life-threatening or very serious diseases and rare disorders. Venn Life Sciences Holdings PLC is engaged in a Clinical Research Organisation (CRO) providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organisations.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.